Evidence map›Paper›PMID 37693119›Full record

ArticleHemaSphere2023

Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.

Minna Harmanen, Tuula Klaavuniemi, Marc Sorigue, Madiha Khan, Roosa Prusila, Esa Kari, Erika Alanne, Aino Rajamäki, Kaisa Sunela, Arja Jukkola and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Minna HarmanenDepartment of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.
Tuula KlaavuniemiDepartment of Oncology, Mikkeli Central Hospital, Southern Savonia Municipality District, Mikkeli, Finland.
Marc SorigueDepartment of Hematology, ICO-Badalona, Hospital Germans Trias i Pujol, IJC, LUMN, Badalona, Spain.
Madiha KhanDepartment of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.
Roosa PrusilaDepartment of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Esa KariDepartment of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Erika AlanneDepartment of Oncology and Radiotherapy, Turku University Hospital, Western Finland, Cancer Center, Turku, Finland.
Aino RajamäkiDepartment of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.
Kaisa SunelaDepartment of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Arja JukkolaDepartment of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Esa JantunenInstitute of Clinical Medicine, University of Eastern Finland and Department of Medicine, North Carelia Central Hospital, Joensuu, Finland.
Juan-Manuel SanchoDepartment of Hematology, ICO-Badalona, Hospital Germans Trias i Pujol, IJC, LUMN, Badalona, Spain.
Sanna KetolaDepartment of Oncology, Hospital Nova of Central Finland, Jyväskylä, Finland.
Hanne KuitunenCancer Center and Medical Research Center, Oulu University Hospital, Oulu, Finland.
Tuomas SelanderScience Service Center, Kuopio University Hospital, Kuopio, Finland.
Aino RönkäDepartment of Oncology and Radiotherapy, Kuopio University Hospital, Kuopio, Finland.
Outi KuittinenDepartment of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37693119
PMCPMC10489256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.